Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis

Arthritis Care and Research

Volumn 61, Issue 11, 2009, Pages 1580-1585

  Young, Hee Rho ^a   Chung, Cecilia P ^a   Oeser, Annette ^a   Solus, Joseph ^a   Asanuma, Yu ^b   Sokka, Tuulikki ^c   Pincus, Theodore ^d   Raggi, Paolo ^e   Gebretsadik, Tebeb ^a   Shintani, Ayumi ^a   Stein, C Michael ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

^d NYU HOSPITAL FOR JOINT DISEASES   (United States)

^e EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID A PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; MYELOPEROXIDASE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ADULT; ARTERY CALCIFICATION; ARTICLE; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; CONTROL GROUP; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; REGRESSION ANALYSIS; RHEUMATOID ARTHRITIS; STATISTICAL SIGNIFICANCE;

ADULT; AGE OF ONSET; AGED; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; E-SELECTIN; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-1ALPHA; INTERLEUKIN-6; LOGISTIC MODELS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEUTROPHILS; PEROXIDASE; RISK FACTORS; SERUM AMYLOID A PROTEIN; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70449515416     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.25009     Document Type: Article

References (42)

1. Chung CP, Oeser A, Raggi P, Gebretsadik T, Shintani AK, Sokka T, et al. Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum 2005;52:3045-3053 (Pubitemid 41447084)
2. Symmons DP, Jones MA, Scott DL, Prior P. Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol 1998;25:1072-1077 (Pubitemid 28350878)
3. Chung CP, Oeser A, Avalos I, Gebretsadik T, Shintani A, Raggi P, et al. Utility of the Framingham risk score to predict the presence of coronary atherosclerosis in patients with rheumatoid arthritis. Arthritis Res Ther 2006;8:R186. (Pubitemid 46211007)
4. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-1695
5. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342: 836-843 (Pubitemid 30165206)
6. Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, et al. Inflammatory markers and cardiovascular disease (the Health, Aging and Body Composition [Health ABC] Study). Am J Cardiol 2003;92:522-528 (Pubitemid 37013402)
7. Johnson BD, Kip KE, Marroquin OC, Ridker PM, Kelsey SF, Shaw LJ, et al. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 2004; 109:726-732
8. Inoue M, Itoh H, Ueda M, Naruko T, Kojima A, Komatsu R, et al. Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation 1998;98:2108-2116 (Pubitemid 28527469)
9. Avanzas P, Arroyo-Espliguero R, Cosin-Sales J, Quiles J, Zouridakis E, Kaski JC. Multiple complex stenoses, high neutrophil count and C-reactive protein levels in patients with chronic stable angina. Atherosclerosis 2004;175:151-157 (Pubitemid 38750203)
10. Waehre T, Yndestad A, Smith C, Haug T, Tunheim SH, Gullestad L, et al. Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors. Circulation 2004;109:1966-1972 (Pubitemid 38544487)
11. Zhang R, Brennan ML, Fu X, Aviles RJ, Pearce GL, Penn MS, et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001;286:2136-2142 (Pubitemid 34041599)
12. Gurbel PA, Kreutz RP, Bliden KP, DiChiara J, Tantry US. Biomarker analysis by fluorokine multianalyte profiling distinguishes patients requiring intervention from patients with long-term quiescent coronary artery disease: a potential approach to identify atherosclerotic disease progression. Am Heart J 2008;155:56-61. (Pubitemid 350234773)
13. Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AM Jr, et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 1997;96:4219-4225
14. Rohde LE, Lee RT, Rivero J, Jamacochian M, Arroyo LH, Briggs W, et al. Circulating cell adhesion molecules are correlated with ultrasound-based assessment of carotid atherosclerosis. Arterioscler Thromb Vasc Biol 1998;18:1765-1770 (Pubitemid 28521067)
15. Asanuma Y, Chung CP, Oeser A, Shintani A, Stanley E, Raggi P, et al. Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. J Rheumatol 2006;33:539-545 (Pubitemid 43334577)
16. Rho YH, Chung CP, Oeser A, Solus J, Raggi P, Gebretsadik T, et al. Novel cardiovascular risk factors in premature coronary atherosclerosis associated with systemic lupus erythematosus. J Rheumatol 2008;35:1789-1794
17. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324
18. Solus J, Chung CP, Oeser A, Avalos I, Gebretsadik T, Shintani A, et al. Amino-terminal fragment of the prohormone brain- type natriuretic peptide in rheumatoid arthritis. Arthritis Rheum 2008;58:2662-2669
19. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990;15:827-832 (Pubitemid 20101575)
20. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation 2002;106:3143-3421
21. Koenker R, Bassett G. Regression quantiles. Econometrica 1978;46:33-50.
22. Walker SH, Duncan DB. Estimation of the probability of an event as a function of several independent variables. Biometrika 1967;54:167-179
23. Harrel FE. Ordinal logistic regression. In: Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. New York: Springer; 2001. p. 331-343
24. Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2407-2415 (Pubitemid 37542989)
25. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2399-2406 (Pubitemid 37542988)
26. Roman MJ, Moeller E, Davis A, Paget SA, Crow MK, Lockshin MD, et al. Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. Ann Intern Med 2006;144:249-256 (Pubitemid 46768207)
27. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-259 (Pubitemid 29063266)
28. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al, and the ATTRACT Study Group. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999;354:1932-1939.
29. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004;50:1761-1769 (Pubitemid 38725087)
30. Del Rincon I, Freeman GL, Haas RW, O'Leary DH, Escalante A. Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis. Arthritis Rheum 2005;52:3413-3423 (Pubitemid 41612207)
31. Hannawi S, Haluska B, Marwick TH, Thomas R. Atherosclerotic disease is increased in recent-onset rheumatoid arthritis: a critical role for inflammation. Arthritis Res Ther 2007;9: R116. (Pubitemid 350239078)
32. Dessein PH, Joffe BI, Singh S. Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res Ther 2005;7:R634-43.
33. Dessein PH, Norton GR, Woodiwiss AJ, Joffe BI, Wolfe F. Influence of nonclassical cardiovascular risk factors on the accuracy of predicting subclinical atherosclerosis in rheumatoid arthritis. J Rheumatol 2007;34:943-951 (Pubitemid 46774836)
34. Urowitz MB, Ibanez D, Gladman DD. Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors. J Rheumatol 2007;34:70-75 (Pubitemid 46106565)
35. Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and anky-losing spondylitis. J Rheumatol 2006;33:2167-2172 (Pubitemid 44749774)
36. Seymour GJ, Ford PJ, Cullinan MP, Leishman S, Yamazaki K. Relationship between periodontal infections and systemic disease. Clin Microbiol Infect 2007;13 Suppl 4:3-10.
37. Hurlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O, et al. Anti-tumor necrosis factor-α treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002;106:2184-2187 (Pubitemid 35222210)
38. Del Porto F, Lagana B, Lai S, Nofroni I, Tinti F, Vitale M, et al. Response to anti-tumour necrosis factor α blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis. Rheumatology (Oxford) 2007;46:1111-1115 (Pubitemid 47050613)
39. Dixon WG, Symmons DP. What effects might anti-TNFα treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFα in cardiovascular pathophysiology. Ann Rheum Dis 2007;66:1132-1136
40. Naranjo A, Sokka T, Descalzo MA, Calvo-Alen J, Horslev- Petersen K, Luukkainen RK et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 2008;10:R30.
41. Takeda N, Manabe I, Shindo T, Iwata H, Iimuro S, Kagechika H, et al. Synthetic retinoid Am80 reduces scavenger receptor expression and atherosclerosis in mice by inhibiting IL-6. Arterioscler Thromb Vasc Biol 2006;26:1177-1183 (Pubitemid 43732130)
42. Detrano R, Guerci AD, Carr JJ, Bild DE, Burke G, Folsom AR, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 2008;358:1336-1345